Literature DB >> 2879276

Opioid receptor binding profile of selected dermorphin-like peptides.

A C Rossi, R de Castiglione, G Perseo.   

Abstract

The receptor binding profile of a selected group of dermorphin-like peptides was determined and correlated with the results of the guinea pig ileum (GPI) and mouse vas deferens (MVD) bioassays and with the currently used antinociception tests in the rat. For the peptides with the characteristic dermorphin D-Ala2-Phe3-Gly4 sequence, a linear negative correlation was found between the reciprocal of sodium shift and relative affinity for the mu-type opioid receptor. For the same peptides, a positive correlation was evidenced between relative potency on GPI and MVD and relative affinity for mu- and delta-type receptors, respectively.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2879276     DOI: 10.1016/0196-9781(86)90091-4

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  4 in total

1.  Opioid activity of dermenkephalin analogues in the guinea-pig myenteric plexus and the hamster vas deferens.

Authors:  S Sagan; A D Corbett; M Amiche; A Delfour; P Nicolas; H W Kosterlitz
Journal:  Br J Pharmacol       Date:  1991-10       Impact factor: 8.739

2.  Activity of mu- and delta-opioid agonists in vas deferens from mice deficient in MOR gene.

Authors:  R Maldonado; C Severini; H W Matthes; B L Kieffer; P Melchiorri; L Negri
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

3.  Deltorphins: a family of naturally occurring peptides with high affinity and selectivity for delta opioid binding sites.

Authors:  V Erspamer; P Melchiorri; G Falconieri-Erspamer; L Negri; R Corsi; C Severini; D Barra; M Simmaco; G Kreil
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

Review 4.  Nature-Derived Peptides: A Growing Niche for GPCR Ligand Discovery.

Authors:  Edin Muratspahić; Michael Freissmuth; Christian W Gruber
Journal:  Trends Pharmacol Sci       Date:  2019-04-05       Impact factor: 14.819

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.